Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Improving T cell therapy for cancer.

Aaron E Foster1, Cliona M Rooney

  • 1Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children's Hospital, Baylor College of Medicine, Houston, Texas 77030, USA.

Expert Opinion on Biological Therapy
|March 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same author

Macrophages as gatekeepers of glioma progression.

Molecular therapy. Oncology·2026
Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial.

Nature medicine·2026
Same author

Multi-parametric profiling of IL-7-augmented GD2.CART products in a phase 1 clinical trial.

iScience·2025
Same author

Tunneling CARs: Increasing CAR T-Cell Tumor Infiltration through the Overexpression of MMP-7 and Osteopontin-b.

Cancer immunology research·2025

Adoptive T cell therapy shows promise for viral infections but faces challenges in cancer treatment due to tumor immune evasion. Research focuses on genetically modifying T cells and conditioning patients to improve cancer therapy effectiveness.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Adoptive T cell therapy is effective against cytomegalovirus (CMV) and Epstein-Barr virus (EBV)-associated lymphoproliferative disease (LPD) in immunocompromised individuals.
  • Tumors in immunocompetent hosts develop immune evasion strategies, hindering T cell-mediated killing and limiting the efficacy of adoptive T cell therapy for cancer.

Purpose of the Study:

  • To review novel strategies for enhancing adoptive T cell therapy in cancer treatment.
  • To explore methods for improving the in vivo performance of transferred T cells against tumors.

Main Methods:

  • Discusses genetic modification of antigen-specific T cells for enhanced anti-tumor activity.
  • Reviews host conditioning techniques to improve the expansion and function of transferred T cells in vivo.

Related Experiment Videos

Main Results:

  • Current T cell therapies are highly effective for specific viral diseases due to the high immunogenicity of infected cells.
  • Tumor immune evasion presents a significant barrier to effective T cell-mediated cancer therapy, requiring strategies to rebalance the tumor:T cell interaction.

Conclusions:

  • Genetic engineering of T cells and host conditioning are key research areas to overcome tumor immune evasion.
  • Improving adoptive T cell therapy necessitates enhancing T cell persistence, function, and overcoming the tumor microenvironment's suppressive effects.